Physician profile
Scott Callaghan
NPI 1497747018
$2,908.41
in general payments reported to CMS, 2019-2025
42 companies · $368 in 2025
The $368 reported for 2025 was less than what a typical Neurology (Psychiatry & Neurology) provider received nationally (typical 2025 total: $454).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $1,206 · 2020: $635 · 2021: $172 · 2022: $376 · 2023: $101 · 2024: $51.32 · 2025: $368.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $520.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $519.95 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Supernus Pharmaceuticals, INC. | $374.09 | 2019-2020 | |
| Abbvie INC. | $347.61 | 2021-2025 | |
| Ucb, INC. | $204.90 | 2019-2025 | Briviact, Bimzelx |
| Teva Pharmaceuticals USA, INC. | $166.44 | 2019-2023 | Austedo Xr |
| Sunovion Pharmaceuticals INC. | $131.19 | 2019-2020 | |
| Emd Serono, INC. | $113.76 | 2019-2020 | |
| Lilly USA, LLC | $112.03 | 2019-2023 | Reyvow, Emgality |
| Avanir Pharmaceuticals, INC. | $104.01 | 2019-2020 | |
| Adamas Pharmaceuticals, INC. | $95.23 | 2019 | |
| Upsher-Smith Laboratories LLC | $89.23 | 2019-2020 | |
| Genzyme Corporation | $86.82 | 2019 | |
| Novartis Pharmaceuticals Corporation | $79.39 | 2019-2022 | |
| Tg Therapeutics, INC. | $78.43 | 2024-2025 | |
| Jazz Pharmaceuticals INC. | $70.22 | 2019-2020 | |
| Amgen INC. | $63.20 | 2019-2020 |
Show all 42 companies
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Scott Callaghan listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.